0R55 Stock Overview
A biotech company, focuses on developing clinical assets. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0063 |
| 52 Week High | €0.097 |
| 52 Week Low | €0.0039 |
| Beta | -2.74 |
| 11 Month Change | -31.52% |
| 3 Month Change | -30.77% |
| 1 Year Change | -84.48% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R55 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 10.5% | 2.0% | 1.7% |
| 1Y | -84.5% | -17.5% | 8.3% |
Return vs Industry: 0R55 underperformed the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0R55 underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| 0R55 volatility | |
|---|---|
| 0R55 Average Weekly Movement | 26.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R55's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0R55's weekly volatility has increased from 20% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| 0R55 fundamental statistics | |
|---|---|
| Market cap | €1.67m |
| Earnings (TTM) | -€7.44m |
| Revenue (TTM) | €2.87m |
0.6x
P/S Ratio-0.2x
P/E RatioIs 0R55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R55 income statement (TTM) | |
|---|---|
| Revenue | €2.87m |
| Cost of Revenue | €0 |
| Gross Profit | €2.87m |
| Other Expenses | €10.31m |
| Earnings | -€7.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 100.00% |
| Net Profit Margin | -259.05% |
| Debt/Equity Ratio | -125.9% |
How did 0R55 perform over the long term?
See historical performance and comparison